1u7kf0g

Independent
scientific experts
nominated by the
European
Commission
Country
Outcome
restriction
following
evaluation of e-
DoI for the
meeting:
Topics on the current Committee
Agenda for which restriction
applies
Product/
substance
Jane Ahlqvist Rastad
Cannot act as
Rapporteur or Peer
reviewer for:
naloxegol; olaparib; saxagliptin,
metformin; ceftaroline fosamil
Marie Louise De Bruin
Full involvement
Stephen Evans
Brigitte Keller-
Stanislawski
Not applicable
Cannot act as
Rapporteur or Peer
reviewer for:
Full involvement
fondaparinux; ofatumumab; pandemic
influenza vaccine (H5N1) (split virion,
inactivated, adjuvanted);
pneumococcal polysaccharide conjugate
vaccine (adsorbed); prepandemic
influenza vaccine (H5N1) (split virion,
inactivated, adjuvanted); human
papillomavirus vaccine [types 16, 18]
(recombinant, adjuvanted, adsorbed);
eltrombopag; pandemic influenza
vaccine (H1N1) (split virion,
inactivated, adjuvanted)
Hervé Le Louet
Full involvement
Lennart Waldenlind
Full involvement
Health care
professiona
ls and
patients
members
Country
Outcome restriction following
evaluation of e-DoI for the meeting:
Topics on the current
Committee Agenda
for which restriction
applies
Product/substance
Filip Babylon
Full involvement
Marco Greco
Full involvement
Kristen Myhr
Full involvement
Albert van der
Zeijden
Cannot act as Rapporteur or Peer Reviewer
in relation to any medicinal product from
the relevant companies for which his
institution receives grants as listed in the
published Declaration of Interest (2013-05-
30)
http://www.ema.europa.eu/docs/en_GB/do
cument_library/contacts/avanderzeijden_DI
.pdf
Pharmacovigilance Risk Assessment Committee (PRAC)
EMA/PRAC/438418/2014 Page 74/75